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Abstract
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human
cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal
cancer treatment, but many patients treated with cetuximab don’t respond or eventually acquire resistance. To
determine how tumor cells acquire resistance to cetuximab, we previously developed a model of acquired resis-
tance using the non–small cell lung cancer line NCI-H226. These cetuximab-resistant (CtxR) cells exhibit increased
steady-state EGFR expression secondary to alterations in EGFR trafficking and degradation and, further, retained
dependence on EGFR signaling for enhanced growth potential. Here, we examined Sym004, a novel mixture of
antibodies directed against distinct epitopes on the extracellular domain of EGFR, as an alternative therapy for CtxR
tumor cells. Sym004 treatment of CtxR clones resulted in rapid EGFR degradation, followed by robust inhibition of
cell proliferation and down-regulation of several mitogen-activated protein kinase pathways. To determine whether
Sym004 could have therapeutic benefit in vivo, we established de novo CtxR NCI-H226 mouse xenografts and
subsequently treated CtxR tumors with Sym004. Sym004 treatment of mice harboring CtxR tumors resulted in
growth delay compared to mice continued on cetuximab. Levels of total and phospho-EGFR were robustly de-
creased in CtxR tumors treated with Sym004. Immunohistochemical analysis of these Sym004-treated xenograft
tumors further demonstrated decreased expression of Ki67, and phospho-rpS6, as well as a modest increase in
cleaved caspase-3. These results indicate that Sym004 may be an effective targeted therapy for CtxR tumors.
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Introduction
The epidermal growth factor receptor (EGFR) is a member of the
human epidermal growth factor receptor (HER) family of receptor
tyrosine kinases that consists of four members: EGFR (ErbB1/HER1),
HER2/neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). Stimulation
of EGFR through ligand binding promotes receptor homodimerization
or heterodimerization with other HER family receptors, leading to acti-
vation of its intrinsic tyrosine kinase [1,2]. Activation of EGFR initiates
various signaling cascades, one of which is the mitogen-activated protein
kinase (MAPK) network. MAPKs belong to a group of intracellular ser-
ine/threonine protein kinases that consist of various members, including
the extracellular signal–regulated kinases 1 and 2 (ERK1/2) and p38
MAPKs (alpha, beta, gamma, delta). Upon activation of EGFR, the
MAPK pathway is initiated through the promotion of Ras binding to
guanosine triphosphate (GTP), which in turn activates RAF kinases
MAPK/extracellular signal-regulated kinases (MEK), and MAPKs.
MAPKs can subsequently activate numerous transcription factors such
as c-Fos, c-Myc, and Elk-1 and numerous protein kinases such as
ribosomal S6 kinase 1 (RSK1) [3]. Collectively, the stimulation of the
MAPK pathway by EGFR has been shown to greatly enhance cell
proliferation, angiogenesis, invasion, and metastasis in cancer cells.
Aberrant expression or activity of EGFR has been identified in
many human epithelial cancers, including non–small cell lung cancer
(NSCLC). Therefore, targeting EGFR has been intensely pursued
over the last three decades as a cancer treatment strategy. One
approach to inhibit the activation of EGFR is through the use of
monoclonal antibodies (mAbs) that bind the extracellular domain
of EGFR to block natural ligand binding. Cetuximab (IMC-225,
Erbitux) is a human/murine chimeric mAb that was developed to
bind to the extracellular domain III of EGFR. This interaction par-
tially blocks the ligand-binding domain and sterically hinders the
correct extended conformation of the dimerization arm on domain II
[4]. The Food and Drug Administration has approved cetuximab
treatment for patients with metastatic colorectal cancer (mCRC) and
head and neck squamous cell carcinoma (HNSCC). However, while
cetuximab has shown beneficial antitumor effects in these cancers,
the majority of patients who initially respond eventually acquire
resistance [1,5,6].
Numerous efforts have been undertaken to define the molecular
mechanisms of acquired resistance to cetuximab [7–14]. Our laboratory
has established panels of cetuximab-resistant (CtxR) clones from the
NSCLC cell line NCI-H226 by exposing these cells in vitro to increas-
ing concentrations of cetuximab. Using this model, we have shown
that impaired EGFR internalization and degradation lead to increased
EGFR surface level expression, increased EGFR kinase activity, and
dependence on EGFR induced signaling pathways [7]. These data
suggest that EGFR remains a molecular target in this setting and that
new therapeutics that can initiate the rapid internalization and robust
degradation of EGFR may be a potent anticancer strategy.
Sym004 is a novel 1:1 mixture of a pair of mAbs (992 and 1024)
directed against nonoverlapping epitopes on EGFR [15,16]. Sym004
inhibits cancer cell growth and survival by blocking ligand binding,
receptor activation, and downstream signaling. Unlike cetuximab,
Sym004 induces rapid and efficient removal of the receptor from
the cell surface by triggering EGFR internalization and degradation.
Additionally, Sym004 has been shown to elicit antibody-dependent
cellular cytotoxicity and complement-dependent cytotoxicity in vivo
[16], while cetuximab has been shown to elicit antibody-dependent
cellular cytotoxicity only [16–19].
In this study, we hypothesized that cells with acquired resistance
to cetuximab retain growth dependency on the EGFR and would
therefore benefit from therapeutic agents that promote EGFR degra-
dation. We found that Sym004 treatment delays the emergence of
acquired resistance to cetuximab in NCI-H226 cells both in vitro
and in vivo. Down-regulation of several MAPK pathways was also
observed in response to Sym004 treatment. The results presented
herein suggest that tumors with acquired resistance to cetuximab




The humanNSCLC cell lineNCI-H226 was provided byDrs J.Minna
and A. Gazdar (University of Texas Southwestern Medical School,
Dallas, TX). The cells were maintained in 10% FBS in RPMI-1640
(Mediatech, Inc, Manassas, VA) with 1% penicillin and streptomycin.
The development of CtxR cells has been described previously [10].
Small Interfering RNA and Transfection
For small interfering RNAs (siRNAs), CtxR cells (HC1, HC4, and
HC8) were transiently transfected with siEGFR (ON-TARGETplus,
SMART pool #L-003114-00; Dharmacon, Lafayette, CO) using
Lipofectamine RNAiMAX according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, CA). The nontargeting siRNA (ON-
TARGETplus Non-targeting Pool, #D-001810-10) was obtained
from Dharmacon as a control. Cells were then lysed for analysis of
protein knockdown by immunoblot analysis after siRNA transfection.
Materials
Cetuximab (IMC-225, Erbitux) was purchased from the Univer-
sity of Wisconsin Pharmacy. Sym004 was generously provided by
Symphogen A/S (Lyngby, Denmark).
Antibodies
All antibodies were purchased from commercial sources as indicated
below: EGFR, pEGFR (Y1173), and HRP-conjugated goat anti-rabbit
IgG and goat anti-mouse IgG were obtained from Santa Cruz Bio-
technology, Inc (Dallas, TX). pEGFR (Y1045), pEGFR (Y1068),
pERK1/2 (T202/Y204), p44/42 ERK1/2, p-rpS6 (S235/236), rpS6,
p-c-RAF (S289/296/301), c-RAF, pRSK1 (S380), RSK1, p-p38
(T180/Y182), and p38 were obtained from Cell Signaling Technology
(Danvers, MA). pERK1/2 (T202/Y204/T185/Y187) was purchased
from Abcam (Cambridge, MA). α-Tubulin was purchased from
Calbiochem (Billerica, MA).
Cell Proliferation Assay
This was performed as previously described [10]. Cells were seeded
in six-well plates. Following treatment, monolayers were analyzed by
crystal violet assay. All treatments were performed in triplicate. Cells
were seeded at 2000 cells per well in 100 μl of media on a 96-well
plate, grown for 24 hours, and then treated with drug for 72 hours
before analysis using the Cell Counting Kit 8 (Dojindo Molecular
Technologies, Rockville, MD) according to the manufacturer’s
instructions. All treatments were performed in quadruplicate.
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Cell Growth Assay In Vivo
Athymic nude mice (4- to 6-week-old males) were obtained from
Harlan Laboratories (Indianapolis, IN). All animal procedures and
maintenance were conducted in accordance with the institutional
guidelines of the University of Wisconsin. Mice were randomized
into treatment or control groups. Parental NCI-H226 (HP), HC1,
or HC4 cells were injected in the dorsal flank of the mouse at respec-
tive day 0 (1 × 106 cells). Once tumors reached 250 mm3, mice were
started on 0.5 mg of cetuximab treatments twice a week by intra-
peritoneal (i.p.) injection. Tumor volume measurements were evalu-
ated by digital calipers and calculated by the formula (p)/6 × (large
diameter) × (small diameter)2.
Immunoblot Analysis
Whole-cell protein lysate was obtained using Tween-20 lysis buffer
(50 mMHepes, pH 7.4, 150 mMNaCl, 0.1% Tween-20, 10% glyc-
erol, 2.5 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM Na3VO4,
1 mM PMSF, 1 mM beta-glycerophosphate (BGP), and 10 μg/ml
leupeptin and aprotinin). Immunoblot analysis was conducted as
previously described [20].
Bromodeoxyuridine Cell Cycle Distribution Analysis
Cells were plated at a density of 800,000 per 100 mm2 plate and
allowed to adhere overnight. The cells were treated with vehicle,
20 μg/ml cetuximab, or 20 μg/ml Sym004 for 24 hours. On the
following day, the cells were pulsed with 10 μM bromodeoxyuridine
for 1 hour. The cells were harvested by trypsinization, washed with
cold phosphate-buffered saline (PBS), and fixed with 70% ethanol
for 20 minutes. The cells were then labeled with a fluorescein
isothiocyanate–conjugated mouse anti-bromodeoxyuridine antibody
and processed according to the manufacturer’s recommendations
(BD Pharmingen, San Jose, CA). The cells were analyzed by flow
cytometry (BD FACScan). ModFit Software (Verity Software House,
Topsham, ME) was used to analyze the data.
Phospho-MAPK Array
Cell lines were analyzed in the panel of phosphorylation profiles of
MAPK and other serine/threonine kinases after treatment with
Sym004 (Human Phospho-MAPK, ARY002B; R&D Systems,
Minneapolis, MN). This array specifically screens for relative levels
of phosphorylation of 26 individual proteins including 9 MAPKs
and other intracellular proteins involved in cellular proliferation.
After treatment with or without Sym004 (50 μg/ml), cell lysates were
incubated with the membrane. Thereafter, a cocktail of biotinylated
detection antibodies, streptavidin-HRP, and chemiluminescent
detection reagents was used to detect the phosphorylated protein.
The relative expression of specific phosphorylated protein was deter-
mined following quantification of scanned images by ImageJ com-
pared with Sym004 and vehicle.
Mouse Xenograft Model
Athymic nude mice (4- to 6-week-old males) were obtained from
Harlan Laboratories. All animal procedures and maintenance were
conducted in accordance with the institutional guidelines of the Uni-
versity of Wisconsin. Mice were randomized into treatment or
control groups. Mice were injected in the dorsal flank of the mouse
at respective day 0 (2 × 106 cells). Once tumors reached 200 mm3,
mice were started on their respective treatments (IgG, cetuximab,
Sym004). The dose of cetuximab and Sym004 for the experiment
was 1, 5, 20, and 50 mg/kg and twice a week by i.p. injection. Tumor
volume measurements were evaluated by digital calipers and calcu-
lated by the formula (p)/6 × (large diameter) × (small diameter)2.
Mouse CtxR Human Tumor Xenografts
Mice were injected with NCI-H226 (2 × 106 cells), and tumors
were allowed to grow to 100 mm3. All mice were randomized to
treatment or control groups and treated with 1 mg/mouse (40 mg/kg)
of either cetuximab or IgG i.p. twice weekly. Tumors were monitored
for cetuximab resistance that was defined as marked tumor growth in
the presence of continued cetuximab therapy. Once CtxR tumors
reached a volume of ∼1000 mm3, mice were grouped according to
similar time points of resistance. At this point, each mouse was treated
with either cetuximab (1 mg) or Sym004 (20 mg/kg) i.p. twice weekly.
Tumor volume measurements were evaluated by digital calipers and
calculated by the formula (p)/6 × (large diameter) × (small diameter)2.
Mouse Tumor Collection and Protein Isolation
Tumors were collected 3 hours after the last cetuximab or Sym004
treatment. Mice were sedated using isoflurane mixed with oxygen
until unconscious. Mice were killed by cervical dislocation, and tumors
were promptly collected, washed in PBS, and frozen with isopentane on
dry ice. Whole-cell protein lysates from tumor samples were obtained
with NP-40 lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl,
1% NP-40, 0.5% deoxycholic acid, 10% glycerol, 2.5 mM EGTA,
1 mM EDTA, 1 mM DTT, 1 mM PMSF, and 10 μg/ml leupeptin
and aprotinin), homogenized by 10 strokes in a tightly fitting Dounce
homogenizer, and quantified. Protein quantitation and immunoblot
analysis were performed as stated above.
Immunohistochemistry
Tumor tissue samples were collected from xenograft tumors. Tumor
samples were fixed in 4% formaldehyde/PBS paraffin-embedded and
section. Sections were heated in 10 mM citrate buffer (pH 6.0) for
EGFR, Ki67, and phospho-rpS6 or in boric acid buffer (pH 8.0) for
cleaved caspase-3 by Decloaking Chamber. Samples were incubated
with rabbit anti-EGFR (Abcam; ab52894, 1:200), rabbit anti-Ki67
(Abcam; ab66155, 1:1000), rabbit cleaved caspase-3 (Biocare, Con-
cord, CA; CP229b, 1:100), and rabbit phospho-rpS6 (S235/236; Cell
Signaling Technology; 1:400). Sections were stained by BrightVision
rabbi t /HRP (Immunolog ic , Duiven, The Nether l ands ;
DPVR110HRP) or LSAB kit/HRP (Dako, Carpinteria, CA). Anti-
body binding was revealed by addition of 3,3′-diaminobenzidine sub-
strate. Tissues were counterstained with Mayer’s hematoxylin (Thermo
Fisher Scientific, Waltham,MA) and were examined using an Olympus
BX51 microscope. The immunohistochemical staining was judged as
follows; Ki67: staining was analyzed with a PC-based image analysis
system (Leica Q500, Cambridge, United Kingdom). With this equip-
ment the positively stained DAB reaction was measured and expressed
as percentage of positive stained area in relation to total analyzed viable
tumor area. Cleaved Caspase-3: no positive cells, low numbers of
positive cells (1+) or moderate numbers of positive cells (2+).
Results
CtxR Clones Have Increased EGFR Activity
We have previously reported that three CtxR clones (HC1, HC4,
and HC8) display a robust CtxR phenotype when challenged with
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increasing doses of cetuximab as compared to HP parental control
cells at 72 hours [10]. To examine the stability of the resistant pheno-
type in vivo, we inoculated 1 × 106 cells of both HP and CtxR clones
HC1 and HC4 into the dorsal flank of athymic nude mice. Tumors
were allowed to grow to 250 mm3 and then treated with 0.5 mg of
cetuximab/mouse i.p. twice weekly for the time indicated. As shown
in Figure 1A, CtxR clones established in culture maintained their
resistant phenotype in the xenograft model system. CtxR clones dis-
played increased steady-state expression of EGFR and EGFR phos-
phorylation (Y1173, Y1068, and Y1045). Increased phosphorylation
levels of downstream signaling molecules, including ERK1/2 (T202/
Y204/T185/Y187), p38 (T180/Y182), RSK1 (S380), c-RAF (S289/
296/301), and rpS6 (S235/236), were detected by immunoblot analy-
sis in the CtxR clones (HC1, HC4, HC8) relative to HP control cells
(Figure 1B). Taken together, these results confirm the establishment
of stable CtxR clones that exhibit robust activation of the EGFR
signaling cascade.
CtxR Clones Are Dependent on EGFR for
Proliferative Potential
To determine if CtxR clones remained dependent on EGFR for
enhanced growth potential, we performed proliferation assays using
siRNAs targeting EGFR. All three CtxR clones displayed prolif-
eration inhibitory effects at 30 nM siEGFR (Figure 2A). Loss of
EGFR expression resulted in loss of activated c-RAF (S289/296/
301) and ERK1/2 (T202/Y204) kinases, demonstrating that
MAPK pathway activation is dependent on EGFR activity. Next,
we treated CtxR clones with 20 μg/ml cetuximab or increasing doses
of Sym004 for 72 hours. All CtxR clones demonstrated statistically
significant, dose-dependent inhibition of proliferation in response
to Sym004 treatment compared to cetuximab or vehicle treatment
(Figure 2B).
Sym004 Effectively Degrades EGFR in CtxR Clones,
whereas Cetuximab Has No Effect on Total and
Phosphorylated EGFR Levels
To investigate if inhibition of cell proliferation by Sym004 is due
to EGFR degradation, we examined the expression levels of EGFR in
CtxR clones treated with 20 μg/ml cetuximab or Sym004 (0.1, 1, 20,
50 μg/ml) for 24 hours (Figure 3A). Since our previous study showed
that small molecule tyrosine kinase inhibitors (TKIs) decreased EGFR
phosphorylation at tyrosine 1173 (Y1173), we chose this site for evalua-
tion of Sym004 [10]. Both activated and total levels of EGFR were
decreased at all doses of Sym004 examined in CtxR clones tested;
Figure 1. CtxR clones have increased EGFR activity. (A) CtxR clones are resistant to cetuximab in vivo. Male athymic nude mice were
injected subcutaneously with 1 × 106 CtxS HP or CtxR cells (HC1 or HC4) into the dorsal flank. Once tumors reached a volume of 250mm3,
mice were treated with 0.5 mg of cetuximab twice weekly. Tumor diameters were measured serially with calipers. Tumor volumes were
calculated and graphed as fold change in tumor volume + S.E. for each cell line. (B) CtxR cells have increased EGFR activity and phos-
phorylation levels of downstream signaling molecules. HP and CtxR clones (HC1, HC4, HC8) were harvested, and protein lysates were
fractionated on sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), followed by immunoblot analysis for the indi-
cated proteins. α-Tubulin was examined as a loading control for each immunoblot analysis.
Neoplasia Vol. 15, No. 10, 2013 Sym004 Can Overcome Resistance to Cetuximab Iida et al. 1199
increasing dosing of Sym004 led to more potent decreases in EGFR
levels. In contrast, cetuximab had no impact on total EGFR levels.
In a time course experiment, CtxR clones were treated with a single dose
of 20 μg/ml Sym004 or cetuximab for 24, 48, or 72 hours (Figure 3B).
The total and phosphorylated EGFR levels were inhibited by Sym004
at all three time points, whereas cetuximab had no effect on total EGFR
and slightly activated EGFR in HC1 and HC4 clones at 24 hours
post treatment. These results demonstrate that Sym004 can effectively
Figure 2. CtxR clones are dependent on EGFR for proliferative potential. (A) siEGFR inhibits the proliferation of CtxR clones. CtxR clones
were plated and treated with 30 nM of EGFR siRNA or 30 nM nontargeting (NT) siRNA. Proliferation was measured at 72 hours after
treatment using the cell counting kit-8 (CCK-8) proliferation assay described in the experimental procedures. Data points are represented
as means ± SEM (n = 4). *P ≤ .05. CtxR clones (HC1, HC4, HC8) were harvested, and protein lysates were fractionated on SDS-PAGE,
followed by immunoblot analysis for the indicated proteins. α-Tubulin was used as a loading control. (B) Sym004 inhibits the proliferation
of CtxR clones. HP and CtxR cell lines (HC1, HC4, HC8) were plated and allowed to adhere for 24 hours before vehicle, cetuximab (20 μg/
ml), or Sym004 treatment: 0.1, 1, 20, or 50 μg/ml. Proliferation was measured at 72 hours after drug treatment using the crystal violet
assay and plotted as a percentage of growth relative to untreated control cells. Data points are represented as means ± SEM (n = 3).
Figure 3. Sym004 effectively degrades EGFR in CtxR clones, whereas cetuximab has no effect on total and phosphorylated EGFR levels.
(A) Sym004 downregulates total and phosphorylated EGFR in CtxR clones. CtxR clones (HC1, HC4, HC8) were treated with vehicle,
cetuximab (20 μg/ml), or Sym004 (0.1, 1, 20, or 50 μg/ml) for 24 hours. Whole-cell protein lysates were fractionated on SDS-PAGE
followed by immunoblot analysis for the indicated proteins. α-Tubulin was used as a loading control. (B) Total and phosphorylated forms
of EGFR remain downregulated 72 hours post Sym004 treatment in CtxR clones. Cells were treated with a single dose of 20 μg/ml
cetuximab or 20 μg/ml Sym004 for 24, 48, or 72 hours. Cell lysates were prepared, and EGFR and phospho-EGFR were determined
by immunoblot analysis.
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downregulate EGFR in all CtxR clones for prolonged periods of time
post treatment.
Multiple MAPK Pathway Proteins Are Inhibited in
CtxR Cells by Sym004 Treatment
CtxR cells exhibited an increase in EGFR expression and activa-
tion, as well as activated MAPK pathway proteins (Figure 1B). To
investigate potential mechanisms by which Sym004 elicits anti-
proliferative effects in CtxR clones, we analyzed the effect of Sym004
treatment on MAPK signaling in each clone using a Human Phospho-
MAPK Array. CtxR clones were treated with vehicle or Sym004
(50 μg/ml) for 24 hours. This Human Phospho-MAPK array includes
26 kinases, 9 of these are MAPKs. As illustrated in Figure 4A, Sym004
decreased phosphorylation in three CtxR clones by averages of 80%
for ERK1, 70% for p38γ, 40% for ERK2, 40% for RSK1, and 30%
for P38β, compared with the vehicle control. Consistent with the
array results, Western blot analysis indicated that phosphorylation
of c-RAF (S289/296/301), ERK1/2 (T202/Y204/T185/Y187),
Figure 4. Multiple MAPK effector molecules are inhibited in CtxR clones by Sym004 treatment. (A) Sym004 inhibited multiple downstream
MAPK effector molecules detected through phospho-kinase array. After treatment with Sym004 (50 μg/ml), cells were collected and cell
extracts were incubated with membranes containing antibodies to 26 individual proteins. The membranes were washed and incubated
with a cocktail of biotinylated detection antibodies, streptavidin-HRP, and chemiluminescent detection reagents to measure the levels of
phosphorylated protein. Quantitation of phosphorylated proteins was completed using scanned images from ImageJ software. Data points
are represented as the mean of duplicate spots. Cell extracts were also fractionated on SDS-PAGE, followed by immunoblot analysis for
the indicated proteins. α-Tubulin was examined as a loading control for each immunoblot analysis. (B) Sym004 can induce a G1-phase cell
cycle arrest in CtxR clones. Cells were treated with 20 μg/ml Sym004 for 24 hours, and cell cycle phase distribution was analyzed
as described in the Materials and Methods section. Data points are represented as means ± SEM (n = 3). *P < .05.
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p38 (T180/Y182), and RSK1 (Ser380) were robustly inhibited after
Sym004 treatment in all CtxR cells.
Next, cell cycle phase distribution of CtxR clones was analyzed
post Sym004 treatment. Flow cytometric analysis demonstrated that
Sym004 induced a strong G1 arrest in Ctx
R cell lines (Figure 4B).
Taken together, these data demonstrate that Sym004 can inhibit
EGFR signaling through the MAPK pathway, ultimately impacting
cell cycle progression in CtxR clones.
Both Cetuximab and Sym004 Delay Tumor Growth in
Cetuximab-Sensitive H226 Cells
To investigate the effects of Sym004 in vivo, mice bearing estab-
lished NCI-H226 [cetuximab-sensitive (CtxS) parental cell line] xeno-
grafts were treated with vehicle control, cetuximab, or Sym004. Mice
were injected in the dorsal flank on day 0 (2 × 106 NCI-H226 cells),
and once tumors reached an average volume of 200 mm3 (∼18 days),
mice were randomly grouped. Cetuximab or Sym004 was admin-
istered through i.p. injection at a dose of 1, 5, 20, or 50 mg/kg
twice weekly for four consecutive weeks. Mouse weight was mea-
sured weekly, and no discernible toxicity was observed in either the
cetuximab or Sym004 treatment group. Treatment with either
cetuximab or Sym004 showed clear dose-dependent antitumor activ-
ity, and both agents significantly delay tumor growth of CtxS H226
xenografts at doses of 5 mg/kg or higher compared to the IgG control
group (Figure 5).
Sym004 Treatment of CtxR Tumors Leads to
Tumor Growth Delay In Vivo
Next, we performed a series of mouse xenograft studies of a pre-
viously developed model of de novo acquired resistance to cetuximab
[7]. To develop acquired resistance to cetuximab in vivo, we inocu-
lated 40 mice with the NSCLC NCI-H226 cell line unilaterally
with 2 × 106 tumor cells in the dorsal flank. Tumors were allowed
to grow to 100 mm3, at which time 30 mice were treated with
cetuximab (1 mg/mouse) and 10 mice were treated with IgG control
(1 mg/mouse) twice weekly by i.p. injection. IgG-treated tumors
grew rapidly uninhibited, whereas cetuximab-treated animals dem-
onstrated tumor control and delayed growth. Tumors were moni-
tored for the development of cetuximab resistance, defined as marked
tumor growth in the presence of continued cetuximab therapy. Once
CtxR tumors reached a volume of ∼1000 mm3, mice were grouped
according to similar size at the time of resistance detection. CtxR was
observed in 21 of 30 tumor xenografts (70%) treated with cetuximab,
similar to previous studies from our laboratory [7]. Thus, a total of
nine CtxR mouse xenograft groups was selected for further study
(21 mice in total). Upon establishment of CtxR mouse groups, one
mouse was maintained on cetuximab (1 mg) therapy, while the other
mouse (or mice) in the group was removed from cetuximab and started
on 20mg/kg Sym004 (i.p. twice weekly). The average tumor volume of
mice treated with IgG alone is included in all groups for comparison
purposes. Eight of 12 (67%) CtxR tumors treated with Sym004
demonstrated a tumor response compared to the cetuximab-treated
mouse in each group, while four (33%) tumors failed to respond. In
Figure 6A, we illustrate six of the nine groups where Sym004 delayed
tumor growth more than 30 days. The black arrow designates the
starting time point of Sym004 treatment.
To further investigate the ability of Sym004 to effectively target
EGFR in large tumors in vivo, we examined total and phospho-EGFR
levels in individual tumors by immunoblot analysis (Figure 6B).
Sym004-treated CtxR tumors had essentially undetectable levels of
EGFR,whereas cetuximab-treatedCtxR tumors retained significant levels
of EGFR. These findings were very similar to the results presented in
Figure 3A. Next, we verified these findings in tissue sections of the tumors
by immunohistochemical analysis of EGFR, as well as markers for cell
proliferation (Ki67) and apoptosis (cleaved caspase-3; Figure 6C ).
Strong membrane and intracellular EGFR staining were observed in
IgG- and cetuximab-treated CtxR tumors. Sym004-treated CtxR tumors
showed moderate intracellular EGFR staining, and no or very limited
membrane staining was seen in the majority of tumors examined.
The highest numbers of Ki67-positive cells (18%) are seen in IgG
followed by cetuximab-treated group (7%), and the lowest numbers
are seen in Sym004-treated group (2%). Cleaved caspase-3 staining
(black arrows) revealed that the most extensive expression was seen in
samples treated with Sym004 followed by cetuximab-treated samples,
and the most restricted expression was seen in IgG-treated samples. As
a survival marker, phospho-rpS6 (S235/S236) was also stained in these
CtxR tumors. CtxR tumors treated with Sym004 demonstrated promi-
nent inhibition of p-rpS6 compared to IgG or cetuximab-treated CtxR
tumors (Figure 6C ). These xenograft studies suggest that Sym004 can
effectively inhibit the growth of large CtxR tumors, providing strong
evidence for the use of Sym004 in the setting of acquired resistance
to cetuximab.
Figure 5. Both cetuximab and Sym004 can effectively control the
growth of CtxS mouse xenograft tumors. NCI-H226 cells were
injected into mice, and tumors were allowed to grow to 200 mm3.
All micewere randomized to treatment or control groups and treated
with cetuximab (1, 5, 20, or 50mg/kg), Sym004 (1, 5, 20, or 50mg/kg),
or IgG (50 mg/kg) i.p. twice weekly.
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Figure 6. Sym004 treatment delays the growth of CtxR xenograft tumors. (A) Growth-inhibitory effects of Sym004 in CtxR tumors in vivo.
Mice were injected with NCI-H226, and tumors were allowed grow to 100 mm3. All mice were randomized to treatment or control groups
and treated with either 1 mg/mouse (40 mg/kg) of cetuximab or IgG i.p. twice weekly. Tumors were monitored for cetuximab resistance,
defined as marked tumor growth in the presence of continued cetuximab therapy. Once CtxR tumors reached a volume > 1000 mm3, mice
were grouped according to similar time points of resistance. At this point, each mouse was treated with either cetuximab or Sym004
i.p. twice weekly. The black arrow designates the starting time point of Sym004 treatment. The average tumor volume of mice treated
with IgG is included in all groups for comparison purposes. (B) Sym004-induced EGFR degradation in vivo. Immunoblot analysis of total
and activated EGFR in CtxR xenograft tumors after cetuximab or Sym004 treatment. C, cetuximab; S, Sym004. (C) The degradation of EGFR
in CtxR tumors corresponds with loss of proliferation and enhancement of apoptosis. CtxR tumor samples after cetuximab or Sym004
treatment in vivo were prepared and analyzed for EGFR, proliferation (Ki67), apoptosis (cleaved caspase-3), and phospho-rpS6 immuno-
histochemistry. Black arrows denote cells positive for cleaved caspase-3. The percentage of Ki67-positive cells and the number of positive
cells for cleaved caspase-3 expression are shown.
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Discussion
EGFR is one of the most highly targeted receptors in oncology due
to its frequent overexpression and aberrant activation in numerous
cancers. The anti-EGFR mAb therapy cetuximab is a Food and Drug
Administration–approved treatment for mCRC [21] and HNSCC
[22] and has shown efficacy in other tumor types such as NSCLC
[23,24]. While cetuximab has demonstrated clinical success, both
intrinsic and acquired resistance is commonly observed. To charac-
terize the mechanisms of resistance to cetuximab in NSCLC, the cell
line NCI-H226 was treated with increasing doses of cetuximab until
resistant cell clones developed. In this model, we found that CtxR
clones had increased EGFR expression and dependency on EGFR
for enhanced proliferative potential [10,11]. Therefore, we hypothe-
sized that Sym004, a novel anti-EGFR mAb mixture that leads to
rapid internalization and degradation of the EGFR [15], may over-
come resistance to cetuximab. The present study demonstrates that
Sym004 can elicit potent antiproliferative effects in CtxR clones,
which corresponded to the degradation of total EGFR. The loss of
EGFR inhibited the activity of multiple MAPK signaling proteins
corresponding to G1 phase cell cycle arrest. De novo xenograft models
of NSCLC (NCI-H226) acquired CtxR further indicated that
Sym004 could significantly delay the growth of large CtxR tumors.
Collectively, these data suggest that Sym004 may be an invaluable
treatment for EGFR-overexpressing CtxR tumors.
Cetuximab is a human/murine chimeric mAb that binds to the
extracellular ligand-binding domain III of EGFR [4,25]. Cetuximab
prevents EGFR ligand binding and sterically hinders dimerization
with other HER receptors; thus, cetuximab has been shown to
inhibit signaling cascades emanating from activated EGFR [4,26].
Sym004 is a mixture of two EGFR-directed antibodies that bind to
two distinct epitopes on domain III [15,16]. Sym004 can inhibit
EGFR activation and downstream signaling pathways but in contrast
to cetuximab, it can induce robust EGFR cross-links on the cell surface
leading to effective internalization and degradation of the receptor
[15,16]. In the present study, increased doses of Sym004 induced
potent antiproliferative effects in CtxR cell lines (Figure 2B), which
corresponded to more dramatic losses in total EGFR levels (Figure 3A);
this finding suggests that loss of EGFR is a central mechanism by
which proliferation is inhibited. Treatment of CtxR cells with cetuximab
had no effect on EGFR levels and slightly enhanced EGFR activity
(Figure 3B). Mandic et al. reported a similar phenomenon in a variety
of different HNSCC cell lines treated with cetuximab [27], indicating
that cetuximab may function as a weak ligand in some cases. While
the current CtxR model has increased dependency on the EGFR, other
models of CtxR have undergone oncogenic shift to other receptor tyro-
sine kinases (RTKs) [28] or constitutive activation of EGFR down-
stream effector molecules [29]; thus, Sym004 may not be an effective
treatment option for all CtxR tumors. Overall, EGFR-dependent CtxR
clones can be effectively targeted with Sym004 through the robust
degradation of EGFR and loss of downstream signaling emanating from
this receptor.
Previous studies in our laboratory have indicated that the CtxR
clones used in this study have increased expression of EGFR ligands
[8]. Further experimentation demonstrated that addition of EGFR
ligands to the heparin binding (HP) CtxS cell line could enhance resis-
tance to cetuximab. This phenomenon was observed by Hatakeyama
et al., where increased expression of HB-EGF was detected in intrinsic
CtxR HNSCC cell lines and in tumor samples from patients with re-
current disease [30]. Pedersen et al. supported these findings by report-
ing that EGF could enhance resistance to cetuximab in numerous cancer
cell lines; interestingly, researchers further showed that Sym004 treat-
ment of the same cell lines yielded less ligand-induced resistance [15].
Therefore, it seems plausible that Sym004-directed degradation
of EGFR in the current CtxR model might overcome compensatory
up-regulation of ligand.
Another mechanism by which Sym004-directed degradation of
EGFR may overcome CtxR is through the inhibition of EGFR
nuclear translocation. Numerous studies have demonstrated that
nuclear EGFR can enhance resistance to cetuximab [8], gefitinib
[31], radiation [32,33], and chemotherapy [34,35]. Previous research
with the current model demonstrated that inhibition of nuclear
EGFR could resensitize resistant clones to cetuximab [8]. Sym004-
directed degradation of EGFR appears to deplete both the cell
membrane component of EGFR, as well as nuclear EGFR, leading
to effective knockdown of the EGFR signaling network. Thus,
Sym004 may play a vital role in overcoming resistance to gefitinib,
radiation, and chemotherapy as well.
The MAPK signaling pathway is one of the main pathways ema-
nating from activated EGFR, and thus, CtxR clones express activated
forms of MAPK pathway proteins (Figure 1B). Sym004 treatment
inhibited two of the four major groups of conventional MAPKs,
including ERK1/2 and p38 MAPK, in addition to RSK1 and c-RAF
(Figure 4A). RSK1 has specifically been shown to play an important
role in promoting cell cycle progression past the G1 checkpoint through
the phosphorylation of p27Kip1 and serum response factor, ultimately
enhancing cyclin D expression [36]. Therefore, inhibition of RSK1
may play a role in the G1 phase cell cycle arrest observed upon
Sym004 treatment (Figure 4B). While the status of MAPK signaling
proteins were analyzed in this study, the functions of other proteins
were likely modulated as well, and therefore, the antiproliferative effects
of Sym004 observed here may not be solely due to MAPK inhibition.
Additionally, while Sym004 yielded potent antiproliferative effects
in vitro, apoptosis was only minimally increased (data not shown).
The antiproliferative effects observed in vitro were also observed in
de novo models of acquired resistance to cetuximab in vitro. De novo
acquired resistant models were chosen for study because they more
accurately portray the cellular events that result in cetuximab resistance
in the clinic. In this model, CtxR xenograft tumors were significantly
growth delayed upon treatment with Sym004 (Figure 6A) compared to
CtxR tumors that were continued on cetuximab therapy. The fact that
67% of CtxR tumors put on Sym004 yielded tumor growth delay
demonstrates a unique property of Sym004 inhibition rather than just
spontaneous reduction in tumor size. While tumor shrinkage was
observed in some mice upon Sym004 treatment, most experienced
a delay in growth; growth delay in tumors of this size (>1000 mm3)
demonstrates that Sym004 can robustly inhibit proliferation, which
may translate into potent antitumor effects in human patients. Addi-
tionally, Sym004 treatment led to robust losses of EGFR and Ki67
staining, while there were minimal changes in cleaved caspase-3 levels
(Figure 6C ). Collectively, the antitumor effects of Sym004 observed
in this model of CtxR may be exerted through modulations in pro-
liferation pathways rather than apoptosis pathways.
Determining why patients with cancer become resistant to anti-
EGFR therapeutics is a major clinical challenge. Data from the pres-
ent study suggest that CtxR tumors may still be addicted to EGFR
signaling, and therefore, using Sym004 may be of great clinical
promise. Degradation of the EGFR, rather than inactivation, is a
powerful anticancer strategy because both kinase-dependent and
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independent functions of EGFR will be abolished. This therapeutic
may also have antitumor effects in the setting of EGFR-activating
mutations (such as L858R and subsequent gatekeeper mutations
such as T790M), EGFR S492R mutations (found in patients with
mCRC yielding resistance to cetuximab [37]), wild-type and mutant
KRAS colorectal tumors (where some KRAS mutant mCRCs may
still contain sensitivity to cetuximab [38,39]), and in the case of
EGFR-overexpressing breast cancers. Sym004 has now undergone
phase I clinical trials in patients with advanced solid tumors, in
which patients treated with multiple doses of Sym004 had manage-
able adverse effects [40]. Sym004 is currently undergoing phase II
testing in CRC and HNSCC (http://clinicaltrials.gov). Overall,
Sym004 is a promising new molecular targeting agent that may pro-
vide more beneficial antitumor effects compared to cetuximab in
EGFR-overexpressing cancers.
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